0001562180-24-002023.txt : 20240301
0001562180-24-002023.hdr.sgml : 20240301
20240301174920
ACCESSION NUMBER: 0001562180-24-002023
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240229
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dahan Michel
CENTRAL INDEX KEY: 0001669737
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 24711928
MAIL ADDRESS:
STREET 1: C/O AKEBIA THERAPEUTICS, INC.
STREET 2: 245 FIRST STREET, SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-02-29
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001669737
Dahan Michel
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
SVP, Chief Operating Officer
false
Common Stock
2024-02-29
4
S
false
8661.00
1.58
D
706932.00
D
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.
/s/ Carolyn Rucci, attorney-in-fact for Michel Dahan
2024-03-01